We are revolutionizing the translational potential of animal models in preclinical research. Discover the latest articles and news about our recent activities.
1 November 2022
PhoenixBio is delighted to be attending AASLD in person at the Walter E. Washington Convention Center in Washington, DC on November 4th - 8th, 2022. We'll be exhibiting our products & services at booth #714. Meet with our team to learn more about PhoenixBio's capabilities and how we can help you advance and deliver tomorrow’s therapies.
6 October 2022
PhoenixBio is thrilled to be attending the European Society of Gene & Cell Therapy Meeting in person at the Edinburgh International Conference Centre in Edinburgh, UK from October 11th - 14th, 2022.
7 September 2022
PhoenixBio is thrilled to be attending the International HBV Meeting in person at the Novotel Paris Centre Tour Eiffel in Paris, France on September 18th - 22nd, 2022. Meet with our team to learn more about PhoenixBio's capabilities and how we can help you advance future therapies for viral hepatitis (HBV, HDV/HBV, HCV), Gene Editing, Gene Therapy, Drug Metabolism, Pharmacokinetics, and Toxicology.
8 June 2022
PhoenixBio is thrilled to be attending EASL's International Liver Congress in person at the ExCeL in London, UK on June 22nd - 26th, 2022. Meet with our team to learn more about PhoenixBio's capabilities and how we can help you advance future therapies for HBV, HDV/HBV, HCV, NASH/NAFLD, Gene Editing, Gene Therapy, Drug Metabolism, Pharmacokinetics, and Toxicology.
12 May 2022
PhoenixBio is delighted to be attending ASGCT in person at the Walter E. Washington Convention Center in Washington, DC on May 16 - 19, 2022. Meet with our team to learn more about PhoenixBio's capabilities and how we can help you advance and deliver tomorrow’s therapies.
3 January 2022
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in developed countries, with an estimated incidence of around 25% worldwide.
9 August 2021
As the liver is the primary site for drug metabolism, the PXB-mouse is the best available model to predict human-specific metabolism prior to clinical trials. Two Studies performed with the support of PhoenixBio through the Chimeric Mouse with Humanized Liver (CMHL) Consortium are highlighted below.
1 April 2021
PhoenixBio Co., Ltd. (“PhoenixBio”) announced today that it has entered into an agreement to partner with Inotiv, Inc. (“Inotiv”) in providing pre-clinical research services utilizing the PXB-mouse® (cDNA-uPA/SCID mouse model with a humanized liver).
